ELRIG announces Prof Hazel Screen and Dr Dave Powell as keynote speakers for Advances in Cell-based Screening 2026

PrecisionLife and Ovation announce results of first phase to develop drug-response biomarkers to quantitively predict the efficacy, safety and tolerability of glucagon-like peptide-1 receptor agonist (GLP-1).

With Rare Disease Day coming up next weekend, we at BIA are taking time to reflect on our important advocacy and thought leadership in this space, but also on what we hope to achieve in terms of boosting our influence collectively alongside our Charity Partner of the Year.

Cancer Research Horizons adds the Oesophageal Cancer Clinical and Molecular Stratification (OCCAMS) study dataset to its growing portfolio of commercially licensable data assets.

It’s been an energising week across the UK life sciences landscape, marked by major investment, important conversations and new opportunities for our community.

ARC has launched Motherlabs Oxford, a new purpose-built life sciences accelerator space at its ARC Oxford campus, expanding its early-stage laboratory offering in response to sustained demand across the sector.

The Cell and Gene Therapy Catapult (CGT Catapult) has published new insights into the UK’s CGT clinical trials in its 2025 Advanced Therapy Medicinal Product (ATMP) Clinical Trials Database.